3-(哌啶-4-基)丙酸盐酸盐 | 51052-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(哌啶-4-基)丙酸盐酸盐
• 英文名称: 3-(4-piperidyl)propanoic acid hydrochloride
• 英文别名: 3-(4-piperidyl)propionic acid hydrochloride；3-(4-piperidinyl)propionic acid hydrochloride；3-(4-Piperidyl)propionic hydrochloride；3-[4]Piperidyl-propionsaeure; Hydrochlorid；3-(piperidin-4-yl)propionic acid hydrochloride；4-(2-carboxyethyl)-piperidine hydrochloride；3-(Piperidin-4-yl)propanoic acid hydrochloride；3-piperidin-4-ylpropanoic acid;hydrochloride
• CAS: 51052-79-0
• 化学式: C₈H₁₅NO₂*ClH
• mdl: MFCD06202371
• 分子量: 193.674
• InChiKey: XJKGRWLZAWTSOY-UHFFFAOYSA-N

物化性质

• 熔点：
  241-242 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -1.96
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-(哌啶-4-基)丙酸盐酸盐 在 水 、 1-羟基苯并三唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 生成 (R)-1-[3-(1-benzyloxycarbonyl-4-piperidyl)propionyl]-3-piperidinecarboxylic acid
  参考文献：
  名称：

  A Practical Synthesis of the Platelet Fibrinogen Antagonist, Elarofiban

  摘要：

  Elarofiban is a novel, nonpeptide, orally active fibrinogen receptor antagonist useful for the treatment of platelet mediated thrombotic disorders (Costanzo, M. J.; Hoekstra, W. J.; Maryanoff, B. E. WO, 97/41102,1997). Herein we describe the process research that was carried out for the synthesis of elarofiban that eventually led to the development of a safe and cost-effective commercial scale process.

  DOI：

  10.1021/op034103o
• 作为产物：
  描述：

  3-[1-(acetyl)-4-piperidinyl]propionic acid 在 盐酸 作用下， 生成 3-(哌啶-4-基)丙酸盐酸盐
  参考文献：
  名称：

  EP1227090

  摘要：

  公开号：

文献信息

• [EN] BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS BIFONCTIONNELS POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021083949A1

  公开（公告）日：2021-05-06

  The invention provides bifunctional compounds of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I). The compounds cause the degradation of SMARCA2 via the targeted ubiquination of SMARCA2 protein and subsequent proteasomal degradation and are thus useful for the treatment of cancer. The targeting ligand is of formula (TL).

  该发明提供了式（I）的双功能化合物或其药用可接受的盐。式（I）。这些化合物通过靶向泛素化SMARCA2蛋白并随后的蛋白酶体降解来导致SMARCA2的降解，因此对于癌症的治疗是有用的。靶向配体的化学式为（TL）。
• Piperazine derivatives, medicaments comprising these compounds, their
  申请人：Dr. Karl Thomae GmbH

  公开号：US05922717A1

  公开（公告）日：1999-07-13

  The present invention relates to piperazine derivatives of the general formula ##STR1## in which R.sub.a, Y.sub.1 to Y.sub.3 and E are defined herein, tautomers thereof, stereoisomers thereof, including their mixtures, and salts thereof, and in particular physiologically tolerated salts thereof with inorganic or organic acids or bases. These compounds have valuable pharmacological properties, such as aggregation-inhibiting activity. This invention also relates to medicaments comprising these compounds and to processes for the preparation of these compounds.

  本发明涉及一般式##STR1##的哌嗪衍生物，其中R.sub.a，Y.sub.1至Y.sub.3和E在此定义，其互变异构体，立体异构体，包括它们的混合物，以及其盐，特别是与无机或有机酸或碱的生理耐受盐。这些化合物具有有价值的药理特性，如抑制聚集活性。本发明还涉及包含这些化合物的药物和制备这些化合物的方法。
• Certain diacyl hydrazine derivatives
  申请人：Zeneca Limited

  公开号：US05612373A1

  公开（公告）日：1997-03-18

  The invention concerns acid derivatives of formula I R.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --GI and pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, X.sup.1, Q, X.sup.2 and G have the meanings given in the specification. The invention also concerns processes for the preparation of the acid derivatives of formula I, pharmaceutical compositions containing them and their use as inhibitors of the binding of fibrinogen to glycoprotein IIb/IIIa.

  这项发明涉及公式I的酸衍生物R.sup.1 --CON(R.sup.2)--N(R.sup.3)CO--X.sup.1 --Q--X.sup.2 --GI及其在药理学上可接受的代谢易降解酯或酰胺，以及其药理学上可接受的盐，其中R.sup.1，R.sup.2，R.sup.3，X.sup.1，Q，X.sup.2和G具有规范中给定的含义。该发明还涉及制备公式I的酸衍生物的过程，含有它们的药物组合物以及它们作为抑制纤维蛋白原与糖蛋白IIb/IIIa结合的用途。
• [EN] HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF BRAF<br/>[FR] COMPOSÉS HÉTÉROBIFONCTIONNELS EN TANT QU'AGENTS DE DÉGRADATION DE BRAF
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021255213A1

  公开（公告）日：2021-12-23

  Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.

  本发明提供了一种能够特异性降解BRAF的化合物。这些化合物可用于治疗各种癌症。
• 4-Amino-2-piperidino-quinazolines
  申请人：Pfizer Inc.

  公开号：US04243666A1

  公开（公告）日：1981-01-06

  Regulators of the cardiovascular system and, in particular, in the treatment of hypertension having the formula ##STR1## wherein R is lower alkyl; X, is a 3- or 4-position substituent and is --(CH.sub.2).sub.n CONR.sup.1 R.sup.2, --O(CH.sub.2).sub.n CONR.sup.1 R.sup.2 or ##STR2## wherein n is 0, 1 or 2; R.sup.1 is hydrogen or lower alkyl, and R.sup.2 is lower alkyl; lower alkenyl, lower alkynyl, phenyl, substituted phenyl, C.sub.3 -C.sub.7 cycloalkyl; lower alkyl substituted by phenyl, substituted phenyl, C.sub.3 -C.sub.7 cycloalkyl, halogen, trifluoromethyl, hydroxy, lower alkoxy, lower alkoxycarbonyl, phenoxy, substituted phenoxy or --NR.sup.3 R.sup.4 wherein R.sup.3 and R.sup.4 each represent hydrogen, lower alkyl, lower alkanoyl or lower alkylsulfonyl; with the proviso that any O, N or halogen atom in R.sup.2 is separated by at least 2 carbon atoms from the nitrogen atom to which R.sup.2 is attached; or R.sup.1 and R.sup.2 taken together with the nitrogen atom to which they are attached form a morpholino group optionally substituted by one or two lower alkyl groups, or a 1,2,3,4-tetrahydroisoquinolyl group optionally substituted on the benzene ring portion by one or two lower alkoxy groups; the pharmaceutically acceptable bioprecursors therefor, and the pharmaceutically acceptable acid addition salts thereof.

  心血管系统的调节剂，尤其是治疗高血压的化合物的公式为##STR1##其中R是较低的烷基；X是3-或4-位取代基，为--(CH.sub.2).sub.n CONR.sup.1 R.sup.2，--O(CH.sub.2).sub.n CONR.sup.1 R.sup.2或##STR2##其中n为0、1或2；R.sup.1为氢或较低的烷基，而R.sup.2为较低的烷基；较低的烯基，较低的炔基，苯基，取代苯基，C.sub.3-C.sub.7环烷基；较低的烷基被苯基，取代苯基，C.sub.3-C.sub.7环烷基，卤素，三氟甲基，羟基，较低的烷氧基，较低的烷氧羰基，苯氧基，取代苯氧基或--NR.sup.3 R.sup.4取代的；其中R.sup.3和R.sup.4分别表示氢，较低的烷基，较低的烷酰基或较低的烷基磺酰基；但R.sup.2中的任何O、N或卤原子与R.sup.2连接的氮原子至少相隔2个碳原子；或R.sup.1和R.sup.2与它们连接的氮原子一起形成一个吗啡基，该吗啡基可以选择地被一个或两个较低的烷基取代，或者一个1,2,3,4-四氢异喹啉基，该基可以选择地在苯环部分被一个或两个较低的烷氧基取代；其药用上可接受的生物前体，以及其药用上可接受的酸加盐。